12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TC-6987: Phase II started

Targacept began a double-blind, placebo-controlled, U.S. Phase II trial in about 120 patients to evaluate once-daily oral TC-6987 for 4 weeks. Patients will receive...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >